The influence of comorbidities on COVID-19 outcomes has been recognized since the
earliest days of the pandemic. But establishing causality and determining underlying …

Viral infections are a leading cause of myocarditis and pericarditis worldwide, conditions that
frequently coexist. Myocarditis and pericarditis were some of the early comorbidities …

Studies have demonstrated that at least 20% of individuals infected with SARS-CoV-2
remain asymptomatic,,–. Although most global efforts have focused on severe illness in …

Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

Background Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …

Background The impact of COVID-19 on physical and mental health and employment after
hospitalisation with acute disease is not well understood. The aim of this study was to …

As of May 2022, there have been over 524 million confirmed cases of COVID-19 (10). The
pandemic has thus far claimed approximately 6.2 million lives (10). Vaccination is having a …

Importance Continuous positive airway pressure (CPAP) and high-flow nasal oxygen
(HFNO) have been recommended for acute hypoxemic respiratory failure in patients with …

Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2,
there is little information about vaccine efficacy against variants of concern (VOC) in …